Nov 30 (Reuters) - Ablynx NV :
* Ablynx achieves first milestone as part of collaboration with Novo Nordisk
* Ablynx to receive 1 million euro ($1.06 million) success fee
* Ablynx received an upfront license fee of 5 million euros and will receive up to 4 million euros in research funding during the initial three year research term of the collaboration
* Ablynx is eligible to receive potential development, regulatory and commercial milestone payments of up to 182 million euros plus tiered royalties on the annual net sales Source text for Eikon: Further company coverage: ($1 = 0.9409 euros) (Gdynia Newsroom)
Our Standards: The Thomson Reuters Trust Principles.